Transfusion‐transmission of hepatitis E virus through red blood cell transfusion but not through platelet concentrates: A case report from Spain

Abstract

AbstractBackgroundFew cases of transfusion‐transmitted hepatitis E virus (HEV) have been published in Spain. Here, we describe a well‐characterized lookback investigation of a transfusion‐transmitted HEV case at the Community Centre for Blood and Tissues of Asturias (Spain).Case ReportA female patient with chronic myeloid leukemia underwent an allogeneic bone marrow transplant in March 2019 and showed alterations in liver function shortly afterwards. This patient received blood components from 30 different donors in the 3 months before the transplant. Frozen plasma samples from these donations were investigated for the presence of HEV‐RNA. One frequent donor was identified as asymptomatic HEV RNA‐positive at the time of his whole blood donation. The investigation revealed that this donor's plasma unit, originally intended for the fractionation industry, had a viral RNA concentration of 1.9 × 104 copies/mL. HEV RNA was detected initially in the index patient who received the red cell concentrate from this donor 25 days after the transfusion. HEV RNA isolated from both donor and recipient were identified as subtype 3f. The recipient of platelet concentrate (PC), treated with a riboflavin‐based pathogen reduction technology (PRT) was not infected, being negative for the presence of HEV IgM, IgG, and HEV RNA before and after the transfusion.ConclusionThis case study shows that HEV was transmitted through red cell transfusion to a recipient, while the patient who received riboflavin/UV light treated PC did not develop signs of infection. A causal relationship between PRT treatment of the PC and the non‐transmission of HEV remains to be established.